



MAGLUMI® SHBG (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of SHBG in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in the diagnosis of individuals with suspected or confirmed androgen disorders.

SUMMARY

Sex hormone-binding globulin (SHBG) is a glycoprotein responsible for blood transport of testosterone and estradiol, modulating their serum concentrations in biological active format and influencing their bioavailability^{1,2}. SHBG is composed of two identical subunits. SHBG is synthesized mainly in the liver and has a higher binding affinity to testosterone than estradiol³. SHBG concentration is a major factor regulating their distribution between the protein-bound and free states. A small part of biologically active steroids are free in the circulation with the remainder being bound mostly to SHBG and albumin⁴. Blood SHBG concentrations depend on the androgen/estrogen balance, thyroid hormones and dietary factors². The concentration of SHBG is increased by estrogens and decreased by androgens. As a result, SHBG concentrations are higher in women versus men⁵. Pregnant women have markedly higher SHBG serum concentrations due to their increased estrogen production.

The measurement of SHBG can be an important indicator of androgen level. Blood SHBG concentrations are affected by a number of different diseases. Elevated SHBG levels can be seen in men with hyperthyroidism, androgen insensitivity. Decreased SHBG concentrations are found in men with hypothyroidism and androgen replacement therapy; while women with hirsutism, virilism, polycystic ovarian syndrome (PCOS), elevated androgen levels and obesity also have decreased SHBG concentrations^{6,7}.

TEST PRINCIPLE

Sandwich chemiluminescence immunoassay.

The sample, buffer, magnetic microbeads coated with anti-SHBG monoclonal antibody are mixed thoroughly, incubating and performing a wash cycle after a precipitation in a magnetic field. ABEI labeled with another anti-SHBG monoclonal antibody are then added, reacting to form sandwich complexes and incubating. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of SHBG present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with anti-SHBG monoclonal antibody (~10.0 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	2.5 mL	2.0 mL	1.0 mL
Lyophilized Calibrator Low	A low concentration of SHBG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Lyophilized Calibrator High	A high concentration of SHBG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Buffer	Tris-HCl buffer, NaN ₃ (<0.1%).	23.5 mL	13.0 mL	7.8 mL
ABEI Label	ABEI labeled with anti-SHBG monoclonal antibody (~50.0 ng/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	23.5 mL	13.0 mL	7.8 mL
Diluent	PBS buffer, NaN ₃ (<0.1%).	15.0 mL	10.0 mL	5.0 mL
Lyophilized Control 1	A low concentration of SHBG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Lyophilized Control 2	A high concentration of SHBG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
The calibrators and controls are lyophilized and must be reconstituted with distilled or deionized water, refer to the Assay Procedure section.				

The control barcode labels are provided.

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay .
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handing during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.
- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks



0123



130202515M: 100 tests/kit

130602515M: 50 tests/kit

130702515M: 30 tests/kit

On-board	4 weeks
Stability of Calibrator	
Unopened at 2-8°C	until the stated expiration date
On-board (Reconstituted)	5 days
Opened at 2-8°C (Reconstituted)	14 days
Frozen at -20°C (Reconstituted)	6 months
Frozen and thawed cycles (Reconstituted)	no more than 1 time

Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 18-25°C (Reconstituted)	8 hours
Opened at 2-8°C (Reconstituted)	14 days
Frozen at -20°C (Reconstituted)	6 months
Frozen and thawed cycles (Reconstituted)	no more than 1 time

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel.
Plasma	K2-EDTA, Na2-EDTA, heparin lithium or heparin sodium

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 10 µL.

Specimen Storage

Specimens removed from the separator, red blood cells or clot may be stored up to 8 hours 18-25°C, or 72 hours at 2-8°C, or 2 months frozen at -20°C or colder. Frozen specimens subjected to up to 1 freeze/thaw cycle have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Samples, SHBG concentrations above the analytical measuring interval, can be diluted with Diluent either automated dilution protocol or manual dilution procedure. The recommended dilution ratio is 1:10. The concentration of the diluted sample must be >25 nmol/L.
- For manual dilution, multiply the result by the dilution factor. For dilution by the analyzers, the analyzer software automatically takes the dilution into account when calculating the sample concentration.

Note: The SHBG antigen tends to aggregate⁸. This may lead to non-linear dilution behavior in certain individual samples.

PROCEDURE

Materials Provided

SHBG (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Distilled water or deionized water.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3, MAGLUMI X6, or Integrated System Biolumi 8000 and Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.

Preparation of Calibrators and Controls

- Reconstitute Calibrator Low and Calibrator High with 1.0 mL of distilled water or deionized water. Allow the vials to stand for 20 minutes at room temperature, then mix gently before use (avoid foam formation), and transfer to dedicated calibration tubes (transfer Calibrator Low to a colorless-base tube, transfer Calibrator High to a blue-base tube). It is recommended to separate the reconstituted calibrator into several aliquots by 500 µL per vial and freeze at -20°C. Calibrators and reagent lot numbers are lot specific. Do not use calibrators that match with a different reagent lot in the same assay.
- Reconstitute Control 1 and Control 2 with 1.0 mL of distilled water or deionized water. Allow the vials to stand for 20 minutes at room temperature, then mix gently before use (avoid foam formation), and transfer to centrifuge tube. It is recommended to separate the reconstituted controls into several aliquots by 250 µL per vial and freeze at -20°C. Controls and reagent lot numbers are lot specific. Do not use controls that match with a different reagent lot in the same assay.

Preparation of the Reagent

- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
 - Execute recalibration according to the calibration interval required in this package insert.
- Quality Control
- When new lot used, check or edit the quality control information.
 - Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.
- Sample Testing
- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: The assay has been standardized against the WHO 2nd International Standard for SHBG from the National Institute for Biological Standards and Control (NIBSC) code 08/266.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.
- Every 14 days.
- The analyzer has been serviced.
- Control values lie outside the specified range.
- Each time a new kit is used.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published guidelines ⁸.

Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory's quality control procedures, quality control could be performed by running the SHBG assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi system and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.

If the controls in kit are not enough for use, please order SHBG (CLIA) Controls (REF: 160201427MT) from Snibe or our authorized distributors for more.

RESULTS

Calculation

The analyzer automatically calculates the SHBG concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in nmol/L. For further information please refer to the Analyzer Operating Instructions.

Conversion factor: nmol/L x 0.095=µg/mL

Interpretation of Results

The expected values for the SHBG assay were obtained by testing 261 males and 254 females in China, and gave the following expected values. All subjects were apparently healthy, non-pregnant without intake of any contraceptive or relevant prescription drugs.

	Age (years)	Number	Median (nmol/L)	5.0 th -95.0 th percentiles (nmol/L)
Males	20-49	135	30.2	18.0-53.4
	≥50	126	39.1	18.7-74.2
Females	/	254	62.4	28.3-134

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory establish its own reference interval.

LIMITATIONS

- Results should be used in conjunction with patient's medical history, clinical examination and other findings.
- If the SHBG results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- Oral contraceptives and antiepileptic drugs may affect serum or plasma SHBG level, those who take these medicines should report to the doctor prior to measurement of serum or plasma SHBG.
- For patients presenting with cirrhosis or sub-clinical thyroid conditions, carefully evaluate results as this condition can potentially cause erroneously elevated SHBG results.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies^{9,10}. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed¹¹.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.

SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n = 180). The following results were obtained:

Sample	Mean (nmol/L) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (nmol/L)	%CV	SD (nmol/L)	%CV	SD (nmol/L)	%CV
Serum Pool 1	18.140	0.417	2.30	0.247	1.36	0.666	3.67
Serum Pool 2	75.918	2.041	2.69	0.915	1.21	2.749	3.62
Serum Pool 3	128.689	3.403	2.64	2.181	1.69	4.302	3.34
Plasma Pool 1	19.493	0.466	2.39	0.254	1.30	0.799	4.10
Plasma Pool 2	79.389	2.055	2.59	0.805	1.01	2.736	4.74
Plasma Pool 3	131.449	2.885	2.19	1.594	1.21	4.750	3.61
Control 1	30.497	0.706	2.31	0.452	1.48	1.132	3.71
Control 2	69.555	1.941	2.79	0.927	1.33	2.514	3.61

Linear Range

0.800-250 nmol/L (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

0.500-2500 nmol/L (defined by the Limit of Detection and the maximum of the master curve×Recommended Dilution Ratio).

Analytical Sensitivity

Limit of Blank (LoB) =0.200 nmol/L.

Limit of Detection (LoD) =0.500 nmol/L.

Limit of Quantitation (LoQ) =0.800 nmol/L.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous interferents in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Interference	No interference up to	Interference	No interference up to
Bilirubin	20 mg/dL	HAMA	30 ng/mL
Hemoglobin	500 mg/dL	Rheumatoid factor	1500 IU/mL
Intralipid	3000 mg/dL	ANA	6 (S/CO) strong positive

Cross-Reactivity

Cross-reactivity was determined using the assay, three samples containing different concentrations of analyte were spiked with potential cross-reactants in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Cross-reactant	No interference up to	Cross-reactant	No interference up to
AFP	800 IU/mL	Human IgA	40 µg/mL
CBG	60 µg/mL	Human IgG	80 µg/mL
TBG	200 µg/mL	DHT	20 µg/mL
Tg	300 ng/mL	Testosterone	20 µg/mL
Transferrin	4 mg/mL	Estradiol	6 ng/mL
TSH	50 ng/mL		
Fibrinogen	8 mg/mL	Biotin	50 µg/mL

High-Dose Hook

No high-dose hook effect was seen for SHBG concentrations up to 10000 nmol/L.

Method Comparison

A comparison of the SHBG assay with a commercially available immunoassay, gave the following correlations (nmol/L):

Number of samples measured: 117

Passing-Bablok: y=1.0099x+0.1091, r=0.925.

The clinical specimen concentrations were between 1.39 and 253.4 nmol/L.

REFERENCES

1. Rosner W, Hryb DJ, Saeed Khan M, et al. Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane [J]. J Steroid Biochem Molec Biol 1999, 69: 481-485.
2. Rafael Simo, et al. Novel insights in SHBG regulation and clinical implications [J]. Trend in Endocrinology and Metabolism 2015, 26(7): 376-383.
3. Le TN, Nestler JE, Strauss JF III, Wickham EP III. Sex hormone-binding globulin and type 2 diabetes mellitus [J]. Trends Endocrinol Metab. 2012 Jan;23(1):32-40.
4. Burger HG. Androgen production in women [J]. Fertil Steril 2002;77(4): 3-5.
5. Belgorosky A, Escobar ME, Rivarola MA. Validity of the calculation of non-sex hormone-binding globulin-bound estradiol from total testosterone, total estradiol and sex hormone-binding globulin concentrations in human serum [J]. J. steroid Biochem. 1987; 28(4): 429-432.
6. Krassas GE, Poppe K, Glinooer D. Thyroid function and human reproductive health [J]. Endocr Rev 2010; 31(5):702-755
7. Hammond GL, Wu TS, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine [J]. Curr Opin Endocrinol Diabetes Obes. 2012 Jun; 19(3):183-189.
8. CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
9. Robert W. Schroff, Kenneth A. Foon, Shannon M. Beatty, et al. Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy [J]. Cancer Research, 1985, 45(2):879-885.
10. Primus F J, Kelley E A, Hansen H J, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy [J]. Clinical Chemistry, 1988, 34(2):261-264.
11. Boscato L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays [J]. Clinical Chemistry, 1988,34(1):27-33.

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8 °C)		Use-by date
	Contains sufficient for<n> tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	In vitro diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		Reconstitute with

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.

Shenzhen New Industries Biomedical Engineering Co., Ltd.
No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
Tel: +86-755-21536601 Fax: +86-755-28292740



Shanghai International Holding Corp. GmbH (Europe)
Eiffestrasse 80, 20537 Hamburg, Germany
Tel: +49-40-2513175 Fax: +49-40-255726